The largest database of trusted experimental protocols

Tm300

Manufactured by Courage + Khazaka
Sourced in Germany

The TM300 is a skin analysis device that measures transepidermal water loss (TEWL). It is designed to assess skin barrier function by quantifying the rate of water evaporation from the skin's surface.

Automatically generated - may contain errors

6 protocols using tm300

1

Skin Barrier and Hydration Measurements

Check if the same lab product or an alternative is used in the 5 most similar protocols
TEWL was measured using a Tewameter (TM300, Courage & Khazaka, Cologne, Germany). The dermal water content was measured using a Corneometer (CM825, Courage & Khazaka, Cologne, Germany). These measurements were carried out at 23 ± 1 °C and 60 ± 10% humidity.
+ Open protocol
+ Expand
2

Skin Barrier Function in Mice

Check if the same lab product or an alternative is used in the 5 most similar protocols
A Tewameter (TM300) and a Corneometer (CM825, Courage & Khazaka, Cologne, Germany) were used to measure TEWL and stratum corneum water content of the dorsal skin of hairless mice, respectively. TEWL and stratum corneum water content values were automatically calculated and expressed as g/m2h and arbitrary units (AU). These measurements were carried out at 21-22 °C and 50-55% humidity and measured after 0 and 14 days of GS treatment.
+ Open protocol
+ Expand
3

Integrative Rejuvenation Treatment for Facial Skin

Check if the same lab product or an alternative is used in the 5 most similar protocols
For patients with FSD, we sequentially delivered the therapeutic solutions, as 4 ml of vitamin B6, 20 ml of compound glycyrrhizin, 8 ml of metronidazole, and 6 ml of hyaluronic acid equally to the forehead, chin, and cheeks. After the whole procedure of NTJI (about 50 min), the face gets more hydration than before, making them feel more smooth and soft of their skin surface. The treatment was conducted once every 2 weeks for a total of three times. Patients were advised to avoid sun exposure during the treatment and follow-up. Compound glycyrrhizin injection (Japan Minophagen Pharmaceutical Co. Ltd., 20 ml) consists of 40-mg glycyrrhizin, 400-mg aminoacetic acid, and 20-mg cysteine hydrochloride. Vitamin B6 injection (Guangzhou Baiyunshan Tianxin Pharmaceutical Co. Ltd.) contained 50 mg/ml. Metronidazole injection (Shijiazhuang No. 4 Pharmaceutical Co. Ltd.) contained 500 mg per 100 ml. Hyaluronic acid (Wuhan Qizhi Laser Technology Co. Ltd., 20 ml) was at a concentration of 0.05% w/w. A needle-free transdermal jet injector was obtained from QIZHI Inc. (Wuhan, China). The handheld drug delivery device is powered by pressurized carbon dioxide gas. Both VISIA skin analysis imaging system (ICES-003, Canfield Scientific co, Fairfield, NJ) and CK analyzer with three detection probes (TM300, SM 815, and CM 825, Courage-Khazaka, Cologne, Germany) were applied to evaluate the efficacy.
+ Open protocol
+ Expand
4

Skin Tolerance Evaluation of Nanocarriers

Check if the same lab product or an alternative is used in the 5 most similar protocols
In vivo skin human tolerance studies by evaluating biomechanical properties were authorized by the University of Barcelona Ethics Committee on 30 January 2019 (IRB00003099).
Total skin water loss (TEWL) was evaluated with a Tewameter® (TM 300 Courage-Khazaka Electronics GmbH, Cologne, Germany), which measures the amount of water entering the environment (atmosphere) around the epidermal layer of the skin through diffusion and evaporation processes [29 (link),43 (link)]. Ten healthy-skinned participants were recruited and were asked not to use skin-care cosmetics on the flexor side of the left forearm for 24 h before the measures. Small circles were drawn, and records were compiled (baseline records), and then a homogeneous layer of approximately 0.5 g of the gels PRA-NLC-Car and PRA-NLC-Sep was applied to the center of the circle. New measurements were collected after application and at 5, 15 min, 1 h, and 2 h post application. To measure, the probe was pressed and held on the selected area of skin for 60 s. TEWL data (g/m2·h) were expressed as mean ± SD (n = 10).
+ Open protocol
+ Expand
5

Topical Nanogel Therapy for Psoriasis-like Skin Inflammation in Mice

Check if the same lab product or an alternative is used in the 5 most similar protocols
The total number of mice used in the study was 24 (6 animals for each treatment groups). The Balb/c mouse back was topically treated with imiquimod (IMQ) cream (Aldara, Inova) at 62.5 mg for 5 days to evoke psoriasis-like lesions (van der Fits et al., 2009 (link)). Before IMQ activation, nanogels (100 μL) containing 62.5 μg/mL AIPH and 25 μg/mL HPTS with or without heating were applied to the dorsal skin. The phenotypic skin surface was monitored by a digital camera and hand-held microscopy (M&T Optics). The combined score (erythema, scaling, and skin thickness) was estimated to reveal the inflammation severity (scale 0–12) according to the Psoriasis Area and Severity Index (PASI) scoring. The erythema (a*) and transdermal water loss (TEWL) of the skin were estimated by colorimetry (Yokogawa CD100) and a Tewameter (Courage & Khazaka TM300). An in vivo imaging system (IVIS) was used to visualize the cutaneous fluorescence derived from the topically applied nanogels. The nanocarriers were administered to the skin each day for 5 days. The IVIS (PerkinElmer IVIS Lumina LT) was used to image the dorsal skin 24 h postadministration. The excitation and emission wavelengths were set at 430 nm and 445–490 nm, respectively, for IVIS to image the HPTS fluorescence.
+ Open protocol
+ Expand
6

Therapeutic Effects of ASC-Exosomes on Chronic Allergic Dermatitis

Check if the same lab product or an alternative is used in the 5 most similar protocols
All animal procedures were approved by the Institutional Animal Care and Use Committee (IACUC) of Hallym University and performed in accordance with its guidelines. Female SKH-1 mice, aged 6 to 8 weeks, were sensitized with topical applications with 50 μL 2% Oxazolone (Ox). After 1 week, mice were treated topically with 50 μL 0.25% Ox to both flanks once every other day for an additional 7 weeks (total of 21 exposures). After the 8th exposure, when the phenotype of AD-like chronic allergic dermatitis was established, the therapeutic effects of ASC-exosomes were evaluated as follows: 8 h after every Ox exposure, ASC-exosomes (100 μL) at doses of 1, 3, and 10 μg/head, or 0.1% dexamethasone were applied subcutaneously or topically, respectively, thrice a week for 4 weeks (total of 12 treatments). Topical dexamethasone, a type of glucocorticoid with proven efficacy in human AD, served as a positive control. Basal trans-epidermal water loss (TEWL) was measured with a TM300 connected to MPA5 (Courage+Khazaka, Cologne, Germany), and SC hydration, assessed as capacitance, was measured with a Corneometer CM820 (Courage+Khazaka). Skin or blood samples were collected 48 h after the 12th injection of ASC-exosomes.
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!